Therefore, since kynurenine has been implicated as a factor triggering pain hypersensitivity during viral infection, antivirals inhibiting virus entry or a combination of antivirals impacting later stages of influenza virus infection with IDO1 inhibitors may become a novel strategy for treating and mitigating severe influenza cases with accompanying neurological symptoms [217]. The gene discussed is IDO1; the disease is viral infectious disease.